Literature DB >> 24662918

Identification and characterization of small molecules that inhibit nonsense-mediated RNA decay and suppress nonsense p53 mutations.

Leenus Martin1, Arsen Grigoryan1, Ding Wang1, Jinhua Wang1, Laura Breda1, Stefano Rivella1, Timothy Cardozo1, Lawrence B Gardner2.   

Abstract

Many of the gene mutations found in genetic disorders, including cancer, result in premature termination codons (PTC) and the rapid degradation of their mRNAs by nonsense-mediated RNA decay (NMD). We used virtual library screening, targeting a pocket in the SMG7 protein, a key component of the NMD mechanism, to identify compounds that disrupt the SMG7-UPF1 complex and inhibit NMD. Several of these compounds upregulated NMD-targeted mRNAs at nanomolar concentrations, with minimal toxicity in cell-based assays. As expected, pharmacologic NMD inhibition disrupted SMG7-UPF1 interactions. When used in cells with PTC-mutated p53, pharmacologic NMD inhibition combined with a PTC "read-through" drug led to restoration of full-length p53 protein, upregulation of p53 downstream transcripts, and cell death. These studies serve as proof-of-concept that pharmacologic NMD inhibitors can restore mRNA integrity in the presence of PTC and can be used as part of a strategy to restore full-length protein in a variety of genetic diseases. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24662918      PMCID: PMC4040335          DOI: 10.1158/0008-5472.CAN-13-2235

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

Review 1.  Nonsense-mediated mRNA decay in health and disease.

Authors:  P A Frischmeyer; H C Dietz
Journal:  Hum Mol Genet       Date:  1999       Impact factor: 6.150

2.  Druggability of SCF ubiquitin ligase-protein interfaces.

Authors:  Timothy Cardozo; Ruben Abagyan
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

3.  Hypoxic inhibition of nonsense-mediated RNA decay regulates gene expression and the integrated stress response.

Authors:  Lawrence B Gardner
Journal:  Mol Cell Biol       Date:  2008-03-24       Impact factor: 4.272

Review 4.  INGN 201 (Advexin): adenoviral p53 gene therapy for cancer.

Authors:  Dmitry I Gabrilovich
Journal:  Expert Opin Biol Ther       Date:  2006-08       Impact factor: 4.388

5.  Binding of a novel SMG-1-Upf1-eRF1-eRF3 complex (SURF) to the exon junction complex triggers Upf1 phosphorylation and nonsense-mediated mRNA decay.

Authors:  Isao Kashima; Akio Yamashita; Natsuko Izumi; Naoyuki Kataoka; Ryo Morishita; Shinichi Hoshino; Mutsuhito Ohno; Gideon Dreyfuss; Shigeo Ohno
Journal:  Genes Dev       Date:  2006-02-01       Impact factor: 11.361

6.  Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.

Authors:  Liat Linde; Stephanie Boelz; Malka Nissim-Rafinia; Yifat S Oren; Michael Wilschanski; Yasmin Yaacov; Dov Virgilis; Gabriele Neu-Yilik; Andreas E Kulozik; Eitan Kerem; Batsheva Kerem
Journal:  J Clin Invest       Date:  2007-02-08       Impact factor: 14.808

7.  The surveillance complex interacts with the translation release factors to enhance termination and degrade aberrant mRNAs.

Authors:  K Czaplinski; M J Ruiz-Echevarria; S V Paushkin; X Han; Y Weng; H A Perlick; H C Dietz; M D Ter-Avanesyan; S W Peltz
Journal:  Genes Dev       Date:  1998-06-01       Impact factor: 11.361

8.  PTC124 targets genetic disorders caused by nonsense mutations.

Authors:  Ellen M Welch; Elisabeth R Barton; Jin Zhuo; Yuki Tomizawa; Westley J Friesen; Panayiota Trifillis; Sergey Paushkin; Meenal Patel; Christopher R Trotta; Seongwoo Hwang; Richard G Wilde; Gary Karp; James Takasugi; Guangming Chen; Stephen Jones; Hongyu Ren; Young-Choon Moon; Donald Corson; Anthony A Turpoff; Jeffrey A Campbell; M Morgan Conn; Atiyya Khan; Neil G Almstead; Jean Hedrick; Anna Mollin; Nicole Risher; Marla Weetall; Shirley Yeh; Arthur A Branstrom; Joseph M Colacino; John Babiak; William D Ju; Samit Hirawat; Valerie J Northcutt; Langdon L Miller; Phyllis Spatrick; Feng He; Masataka Kawana; Huisheng Feng; Allan Jacobson; Stuart W Peltz; H Lee Sweeney
Journal:  Nature       Date:  2007-04-22       Impact factor: 49.962

9.  NMD is essential for hematopoietic stem and progenitor cells and for eliminating by-products of programmed DNA rearrangements.

Authors:  Joachim Weischenfeldt; Inge Damgaard; David Bryder; Kim Theilgaard-Mönch; Lina A Thoren; Finn Cilius Nielsen; Sten Eirik W Jacobsen; Claus Nerlov; Bo Torben Porse
Journal:  Genes Dev       Date:  2008-05-15       Impact factor: 11.361

10.  Inhibition of nonsense-mediated mRNA decay (NMD) by a new chemical molecule reveals the dynamic of NMD factors in P-bodies.

Authors:  Sébastien Durand; Nicolas Cougot; Florence Mahuteau-Betzer; Chi-Hung Nguyen; David S Grierson; Edouard Bertrand; Jamal Tazi; Fabrice Lejeune
Journal:  J Cell Biol       Date:  2007-09-24       Impact factor: 10.539

View more
  52 in total

1.  Expression of mutant p53 in oral squamous cell carcinoma is correlated with the effectiveness of intra-arterial chemotherapy.

Authors:  Yadong Li; Jinsong Zhang
Journal:  Oncol Lett       Date:  2015-08-27       Impact factor: 2.967

2.  Caspases shutdown nonsense-mediated mRNA decay during apoptosis.

Authors:  J Jia; A Furlan; S Gonzalez-Hilarion; C Leroy; D C Gruenert; D Tulasne; F Lejeune
Journal:  Cell Death Differ       Date:  2015-03-06       Impact factor: 15.828

3.  Loss of the fragile X syndrome protein FMRP results in misregulation of nonsense-mediated mRNA decay.

Authors:  Tatsuaki Kurosaki; Naoto Imamachi; Christoph Pröschel; Shuhei Mitsutomi; Rina Nagao; Nobuyoshi Akimitsu; Lynne E Maquat
Journal:  Nat Cell Biol       Date:  2021-01-08       Impact factor: 28.824

Review 4.  Nonsense-mediated mRNA decay in humans at a glance.

Authors:  Tatsuaki Kurosaki; Lynne E Maquat
Journal:  J Cell Sci       Date:  2016-01-19       Impact factor: 5.285

Review 5.  Leveraging Rules of Nonsense-Mediated mRNA Decay for Genome Engineering and Personalized Medicine.

Authors:  Maximilian W Popp; Lynne E Maquat
Journal:  Cell       Date:  2016-06-02       Impact factor: 41.582

Review 6.  Targeting mutant p53 for efficient cancer therapy.

Authors:  Vladimir J N Bykov; Sofi E Eriksson; Julie Bianchi; Klas G Wiman
Journal:  Nat Rev Cancer       Date:  2017-12-15       Impact factor: 60.716

7.  Discovery of Novel 5-(Piperazine-1-carbonyl)pyridin-2(1H)-one Derivatives as Orally eIF4A3-Selective Inhibitors.

Authors:  Ryo Mizojiri; Daisuke Nakata; Yoshihiko Satoh; Daisuke Morishita; Sachio Shibata; Misa Iwatani-Yoshihara; Yohei Kosugi; Mai Kosaka; Junpei Takeda; Shigekazu Sasaki; Kazuaki Takami; Koichiro Fukuda; Masahiro Kamaura; Shinobu Sasaki; Ryosuke Arai; Douglas R Cary; Yasuhiro Imaeda
Journal:  ACS Med Chem Lett       Date:  2017-09-08       Impact factor: 4.345

8.  Fluorescence Amplification Method for Forward Genetic Discovery of Factors in Human mRNA Degradation.

Authors:  Andrei Alexandrov; Mei-Di Shu; Joan A Steitz
Journal:  Mol Cell       Date:  2016-12-22       Impact factor: 17.970

Review 9.  The Branched Nature of the Nonsense-Mediated mRNA Decay Pathway.

Authors:  Zhongxia Yi; Manu Sanjeev; Guramrit Singh
Journal:  Trends Genet       Date:  2020-09-29       Impact factor: 11.639

10.  Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition.

Authors:  Daichi Inoue; Jacob T Polaski; Justin Taylor; Pau Castel; Sisi Chen; Susumu Kobayashi; Simon J Hogg; Yasutaka Hayashi; Jose Mario Bello Pineda; Ettaib El Marabti; Caroline Erickson; Katherine Knorr; Miki Fukumoto; Hiromi Yamazaki; Atsushi Tanaka; Chie Fukui; Sydney X Lu; Benjamin H Durham; Bo Liu; Eric Wang; Sanjoy Mehta; Daniel Zakheim; Ralph Garippa; Alex Penson; Guo-Liang Chew; Frank McCormick; Robert K Bradley; Omar Abdel-Wahab
Journal:  Nat Genet       Date:  2021-04-12       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.